| Literature DB >> 3144554 |
G G Steger1, C Dittrich, O Schlappack, R Mader, C Herold, W P Brade, A Keller, K Moser.
Abstract
Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO + M over 24 h appeared to be the best tolerated. One partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.Entities:
Mesh:
Substances:
Year: 1988 PMID: 3144554 DOI: 10.1007/bf00398184
Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN: 0171-5216 Impact factor: 4.553